A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 5, 2012, Pages 829-837

  Guzauskas, G F ^a   Hughes, D A ^b   Bradley, S M ^a   Veenstra, D L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROBABILITY; RISK ASSESSMENT; THIOPHENES; TICLOPIDINE;

EID: 84859951080     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.303     Document Type: Article

References (46)

1. Chen, Z.M. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005).
2. Sabatine, M.S. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352, 1179-1189 (2005).
3. Y usuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G. & Fox, K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
4. Wiviott, S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
5. Mega, J.L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
6. Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L. & Topol, E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45, 246-251 (2005).
7. Gurbel, P.A. & Bliden, K.P. Durability of platelet inhibition by clopidogrel. Am. J. Cardiol. 91, 1123-1125 (2003).
8. Mega, J.L. et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376, 1312-1319 (2010).
9. Farid, N.A. et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther. 81, 735-741 (2007).
10. Brandt, J.T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007).
11. Kim, K.A., Park, P.W., Hong, S.J. & Park, J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84, 236-242 (2008).
12. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
13. US Food and Drug Administration. FDA drug safety communication: reduced effectiveness of plavix (clopidogrel) in patients who are poor metabolizers of the drug (2010) 〈http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforpatientsandProviders/ucm203888. htm〉.
14. Mega, J.L. et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553-2560 (2009).
15. Paré, G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363, 1704-1714 (2010).
16. Wallentin, L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376, 1320-1328 (2010).
17. Mega, J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010).
18. Sorajja, P. et al. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J. Am. Coll. Cardiol. 55, 1416-1424 (2010).
19. Bhatt, D.L. What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy? J. Am. Coll. Cardiol. 52, 1060-1061 (2008).
20. Bhatt, D.L. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA 302, 896-897 (2009).
21. Giusti, B. et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am. J. Cardiol. 103, 806-811 (2009).
22. Patti, G., Colonna, G., Pasceri, V., Pepe, L.L., Montinaro, A. & Di Sciascio, G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111, 2099-2106 (2005).
23. Breet, N.J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754-762 (2010).
24. A ngiolillo, D.J. et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J. 25, 1903-1910 (2004).
25. A ngiolillo, D.J. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115, 708-716 (2007).
26. Cuisset, T. et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. 48, 1339-1345 (2006).
27. Hochholzer, W. et al. Time dependence of platelet inhibition after a 600- mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111, 2560-2564 (2005).
28. Montalescot, G. et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48, 931-938 (2006).
29. Müller, I. et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85, 92-93 (2001).
30. von Beckerath, N. et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur. Heart J. 28, 1814-1819 (2007).
31. von Beckerath, N., Taubert, D., Pogatsa-Murray, G., Schömig, E., Kastrati, A. & Schömig, A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112, 2946-2950 (2005).
32. CURRENT-OASIS 7 Investigators, Mehta S.R. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363, 930-942 (2010).
33. Genotype guided comparison of clopidogrel and prasugrel outcomes study (2010) 〈http://clinicaltrials.gov/ct2/show/NCT00995514〉.
34. University of Maryland School of Medicine. School of Medicine Scientist Awarded $11.4 Million to Study Effectiveness of Gene-Directed Therapy for Cardiac Patients. 〈http://somvweb.som.umaryland.edu/absolutenm/templates/? a=1265〉 (2010).
35. Guo, J.J., Pandey, S., Doyle, J., Bian, B., Lis, Y. & Raisch, D.W. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health 13, 657-666 (2010).
36. Garrison, L.P. Jr, Towse, A. & Bresnahan, B.W. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff. (Millwood) 26, 684-695 (2007).
37. Roth, J.A., Garrison, L.P. Jr, Burke, W., Ramsey, S.D., Carlson, R. & Veenstra, D.L. Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics 14, 59-67 (2011).
38. Hughes, D.A., Bayoumi, A.M. & Pirmohamed, M. Current assessment of risk-benefit by regulators: is it time to introduce decision analyses? Clin. Pharmacol. Ther. 82, 123-127 (2007).
39. Main, C. et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol. Assess. 8, iii-iv, xv (2004).
40. Robinson, M. et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Health Technol. Assess. 9, iii-iv, ix (2005).
41. Gray, D., Keating, N.A., Murdock, J., Skene, A.M. & Hampton, J.R. Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction. Lancet 341, 654-657 (1993).
42. Daiichi-Sankyo/Eli Lilly. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Single Technology Appraisal Submission to the National Institute for Health and Clinical Excellence (2009) 〈http://www.nice.org.uk/nicemedia/live/12028/44538/44538. pdf〉.
43. Sullivan, P.W. & Ghushchyan, V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med. Decis. Making 26, 410-420 (2006).
44. Torgerson, D.J. & Raftery, J. Economic notes. Discounting. BMJ 319, 914-915 (1999).
45. Sibbing, D. et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512-518 (2010).
46. Mahoney E.M. et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: Results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction TRITON-TIMI 38. Circulation 121, 71-79 (2010).